Investigation of irisin levels in patients with major depressive disorder
Künye
Okumuş, B., Pusuroğlu, M., Baltacıoğlu, M., Bahçeci, İ. & Bahçeci, B. (2024). Investigation of Irisin Levels in Patients with Major Depressive Disorder. Psychiatry and Behavioral Sciences, 14(1), 40-47. http://doi.org/10.5455/PBS.20230914073554Özet
Objective: Major depressive disorder (MDD) is a common psychiatric disorder. Irisin, produced by proteolysis of FNDC5, is thought to be an exercise -induced hormone that may play a critical role in inducing antidepressant -like effects. Our study aimed to investigate the relationship between irisin and newly diagnosed MDD patients. Methods: This cross-sectional study included 85 first-time diagnosed MDD patients and 81 healthy controls. Patients were diagnosed with MDD using the Structured Clinical Interview Questionnaire for DSM-IV Axis I and II Disorders (SCID-I, II) and the Hamilton Depression Scale (HAM -D). After an overnight fast, 5 ml of peripheral blood was drawn and serum irisin levels were measured. Results: When the effects of age and gender variables were controlled, no statistically significant difference in irisin levels was found between the groups. (F=1.832, p=0.178). When the effects of age, gender and body mass index variables were controlled and a partial correlation was made between irisin and HAMD scores, a significant negative correlation was found between irisin and HAMD scores (p<0.001, r=-0.523). The correlation analysis showed a statistically significant negative relationship between age and irisin levels (p=0.008, r=-0.205). However, when the effects of other variables were controlled and a partial correlation was made, no statistically significant relationship was found (p=0.610, r=-0.207). Conclusion: Our results indicate that irisin levels are associated with the severity of depression. Further studies are needed on the use of irisin as a potential biomarker for predicting clinical course and treatment response in patients with severe MDD.